Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients.
Welt A, Tewes M, Aktas B, O Hoffmann O, Wiesweg M, Ting S, Reis H, Worm K, Richly H, Hense J, Palmer MR, Lee BH, Wendling J, Kossow J, Scheulen ME, Lehnerdt C, Kohl M, Derks C, Skottky S, Haus U, Schmid KW, Kimmig R, Schuler M, Kasper S.
Welt A, et al. Among authors: tewes m.
Breast Cancer Res Treat. 2013 Nov;142(1):81-8. doi: 10.1007/s10549-013-2718-4.
Breast Cancer Res Treat. 2013.
PMID: 24122392